Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosisShow others and affiliations
2019 (English)In: The International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, E-ISSN 1815-7920, Vol. 23, no 11, p. 1155-1161Article in journal (Refereed) Published
Abstract [en]
OBJECTIVE : To investigate how levels of the soluble urokinase plasminogen activator receptor (suPAR) and erythrocyte sedimentation rate (ESR) correlate with disease activity and prognosis in pulmonary tuberculosis (PTB). DESIGN: This was a retrospective analysis of patients with active PTB (n = 500) in Gondar, Ethiopia, for whom the suPAR (n = 301) and ESR (n = 330) were analysed at the start of treatment. Both biomarkers were available for 176 patients. Human immunodeficiency virus (HIV) status, chest X-ray (CXR) findings, classification according to the clinical TBscore and treatment outcome were all recorded. RESULTS : In a multivariable logistic regression analysis adjusted for age, sex and HIV status, surrogate markers of disease activity such as advanced CXR patterns correlated with increased levels of suPAR (adjusted OR [aOR] 8.24, Pamp;lt; 0.001) and of ESR (aOR 1.63, P = 0.030), whereas ESR only correlated significantly with a TBscore amp;gt;6 points. Increased levels of both suPAR and ESR were associated with unsuccessful treatment outcomes (aOR 2.93, P = 0.013; aOR 2.52, P = 0.025). The highest quartile of suPAR (aOR 13.3, P = 0.029) but not ESR levels correlated independently with increased mortality. CONCLUSION: SuPAR and ESR levels correlate with disease activity in PTB; however, the clinical role of these potentially prognostic biomarkers needs to be verified in prospective studies.
Place, publisher, year, edition, pages
INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) , 2019. Vol. 23, no 11, p. 1155-1161
Keywords [en]
chest X-ray; TBscore; HIV; outcome; biomarkers
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:liu:diva-162541DOI: 10.5588/ijtld.18.0634ISI: 000496915300006PubMedID: 31718751OAI: oai:DiVA.org:liu-162541DiVA, id: diva2:1376303
Note
Funding Agencies|Swedish Research Council, Stockholm, SwedenSwedish Research Council [201602043]; Swedish Heart and Lung Foundation (Oscar II Jubilee Foundation), Stockholm, Sweden
2019-12-092019-12-092020-04-29